Kidney Week 2020

Roxadustat Efficacious and Safe in Non-Dialysis-Dependent CKD Patients with Anemia

Researchers in Japan conducted study of roxadustat, an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of...

Limited Physical Function among Patients with CKD and Metabolic Acidosis

The loss of physical function in patients with chronic kidney disease (CKD) is due, in part, to the development...

AKI in Patients with Coronavirus Disease 2019: Systematic Review and Meta-Analysis

As the coronavirus disease 2019 (COVID-19) spread around the world, reports of renal involvement varied across regions. Kam wa...
Association of Plasma Metabolites and Lipids with Kidney Function in Early ADPKD

Metabolic Acidosis and Risk of Progression to Renal Replacement Therapy

Patients with advanced chronic kidney disease (CKD) commonly develop metabolic acidosis, which may be associated with CKD progression to...

Tolvaptan for Treatment of ADPKD in Patients in Japan

Results of the TEMPO (Tolvaptan Efficacy and Safety in the Management of ADPKD and its Outcomes) and REPRISE (Replicating...
Registry Identifies CKD Patients at High Risk of Progression to ESRD

Predictors for Renal Recovery and Mortality in Severe AKI

Critically ill patients often develop acute kidney injury (AKI), a condition that has a broad spectrum of severity. Severe...

Incidence Rate of Proteinuria in Patients with COVID-19 and AKI

Early data on acute kidney injury (AKI) associated with coronavirus disease 2019 (COVID-19) suggested a high prevalence of proteinuria...
Doctor or nutritionist with a diabetic patient explaining glycemic index

Anemia Management in Incident Dialysis Patients over Three Eras in Canada

Amid safety concerns raised following trials of target hemoglobin, several jurisdictions have adopted a more conservative approach to management...

30-Day Hospital Readmissions in Minority Patients with ESRD

Racial/ethnic minorities are 1.5 to 4 times more likely than others to develop end-stage renal disease (ESRD). Among hospitalized...
Autosomal dominant polycystic kidney disease (ADPKD)

Real-World Evidence of Tolvaptan Treatment for Patients with ADPKD

Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary systemic kidney disease characterized by progressive renal damage. Patients with...
Stopping RAS Inhibitors May Worsen Outcomes in CKD

Metabolic Acidosis Associated with Increased Mortality Risk

Patients with metabolic acidosis may develop wide-ranging complications consistent with the fact that many critical cell functions require physiologic...

Characteristics of Patients with ADPKD Treated with Tolvaptan in the United States

The most common inherited kidney disease is autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is the first and only...
SARS-CoV-2 Seroconversion Tied to Out-of-Hospital Sudden Deaths

Risk Factors for AKI in Patients with COVID-19

Patients with coronavirus disease 2019 (COVID-19) may develop acute kidney disease (AKI). The United Kingdom National Institute for Health...
kidney injury

Renal Recovery in Patients with AKI Improved with CRRT

In patients with acute kidney injury (AKI) requiring dialysis (AKI-D), the rate of adverse outcomes is high. There are...
racial treatment disparity

Metabolic Acidosis and Progression of CKD in Racial/Ethnic Groups

Metabolic acidosis is a risk factor for progression of chronic kidney disease (CKD). There are few data available on...

Curated Journal Abstracts

Advertisement
Advertisement